Innate Pharma Total Liabilities
Innate Pharma total liabilities. Based on the latest financial reports, Innate Pharma (IPHA) has total liabilities worth $84.39 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Innate Pharma to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Innate Pharma (2005–2025)
Total liabilities of Innate Pharma from 2005 to 2025. This chart illustrates how Innate Pharma's total liabilities have evolved over time, based on quarterly financial data. Explore IPHA long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Innate Pharma Competitors by Total Liabilities
The table below lists competitors of Innate Pharma ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
FDC International Hotels Corp
TW:2748
|
Taiwan | NT$1.95 Billion |
|
Grupo Clarin S.A.
BA:GCLA
|
Argentina | AR$235.45 Billion |
|
Neo Technical System Co. Ltd
KQ:085910
|
Korea | ₩49.58 Billion |
|
KANGWON Co. Ltd
KQ:114190
|
Korea | ₩86.27 Billion |
|
NeoPharm CO. LTD
KQ:092730
|
Korea | ₩18.97 Billion |
|
Ally Leasehold Real Estate Investment Trust
BK:ALLY
|
Thailand | ฿5.02 Billion |
|
MC Mining Ltd
AU:MCM
|
Australia | AU$30.20 Million |
|
Aurskog Sparebank
OL:AURG
|
Norway | Nkr19.65 Billion |
Liability Composition Analysis (2005–2025)
This chart breaks down Innate Pharma's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Innate Pharma assets under control.
Liquidity & Leverage Metrics
Innate Pharma Total Liabilities Ratios Explained
Innate Pharma total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -3.89 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Innate Pharma's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Innate Pharma (2005–2025)
The table below shows the annual total liabilities of Innate Pharma from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $84.39 Million | -17.45% |
| 2024-12-31 | $102.22 Million | -22.73% |
| 2023-12-31 | $132.29 Million | -13.94% |
| 2022-12-31 | $153.71 Million | -3.96% |
| 2021-12-31 | $160.06 Million | +5.68% |
| 2020-12-31 | $151.45 Million | -17.67% |
| 2019-12-31 | $183.94 Million | -35.23% |
| 2018-12-31 | $283.98 Million | +67.97% |
| 2017-12-31 | $169.07 Million | -13.48% |
| 2016-12-31 | $195.41 Million | -16.45% |
| 2015-12-31 | $233.89 Million | +1355.98% |
| 2014-12-31 | $16.06 Million | +3.00% |
| 2013-12-31 | $15.60 Million | -37.44% |
| 2012-12-31 | $24.93 Million | -25.54% |
| 2011-12-31 | $33.48 Million | +131.02% |
| 2010-12-31 | $14.49 Million | -15.22% |
| 2009-12-31 | $17.10 Million | -12.42% |
| 2008-12-31 | $19.52 Million | +44.10% |
| 2007-12-31 | $13.55 Million | +5.13% |
| 2006-12-31 | $12.89 Million | +174.05% |
| 2005-12-31 | $4.70 Million | -- |
About Innate Pharma
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated t… Read more